BLOGSCAN - Trial Results Via Press Release

Courtesy Health Care Renewal  Mon, 04/20/2009 - 12:23

See posts by Gary Schwitzer on the Schwitzer Health News Blog , and by Merrill Goozner on the GoozNews Blog on a new low in disclosing results of randomized controlled trials.

It seems that Dendreon, the maker of the Provenge vaccine intended to treat prostate cancer, put out a press release that said the vaccine prolongs survival, but was completely lacking in data.

Even preliminary results of the trial have...

Tags:

 

More related items

Vaccine Eyed for Early-Stage Prostate Ca
SAN FRANCISCO (MedPage Today) -- The immunotherapy agent sipuleucel-T (Provenge) appears safe for use earlier in prostate cancer, researchers found.

Most Common Tx for Prostate Ca Not Best Value
SAN FRANCISCO (MedPage Today) -- External beam radiation is the most toxic and expensive among common prostate cancer treatments over the long-term, a national registry study suggested.

New Type of Prostate Cancer Pill Extends Lives
An experimental pill that works differently than other prostate cancer drugs extended the lives of men with spreading cancer by an average of nearly five months.

Burt's Bees Free Head to Toe Starter Kit

Lobe Wonder Ear Support Patches For Earrings,...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com